

## Accepted Manuscript

Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meet

Gabriel Helmlinger, Nidal Al-Huniti, Sergey Aksenov, Kirill Peskov, Melissa Hallow, Lulu Chu, David Boulton, Ulf Eriksson, Bengt Hamrén, Craig Lambert, Eric Masson, Helen Tomkinson, Donald Stanski



PII: S0928-0987(17)30256-7  
DOI: doi: [10.1016/j.ejps.2017.05.028](https://doi.org/10.1016/j.ejps.2017.05.028)  
Reference: PHASCI 4042

To appear in: *European Journal of Pharmaceutical Sciences*

Received date: 11 May 2017  
Revised date: ####REVISEDDATE###  
Accepted date: 12 May 2017

Please cite this article as: Gabriel Helmlinger, Nidal Al-Huniti, Sergey Aksenov, Kirill Peskov, Melissa Hallow, Lulu Chu, David Boulton, Ulf Eriksson, Bengt Hamrén, Craig Lambert, Eric Masson, Helen Tomkinson, Donald Stanski , Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meet, *European Journal of Pharmaceutical Sciences* (2017), doi: [10.1016/j.ejps.2017.05.028](https://doi.org/10.1016/j.ejps.2017.05.028)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

*For submission to:* European Journal of Pharmaceutical Sciences

## **Drug-Disease Modeling in the Pharmaceutical Industry - Where Mechanistic *Systems Pharmacology* and Statistical *Pharmacometrics* Meet**

Gabriel Helmlinger<sup>1a\*</sup>, Nidal Al-Huniti<sup>1a</sup>, Sergey Aksenov<sup>1a</sup>, Kirill Peskov<sup>2</sup>, Melissa Hallow<sup>3</sup>, Lulu Chu<sup>1a</sup>, David Boulton<sup>1b</sup>, Ulf Eriksson<sup>1c</sup>, Bengt Hamrén<sup>1c</sup>, Craig Lambert<sup>1d</sup>, Eric Masson<sup>1a</sup>, Helen Tomkinson<sup>1d</sup>, Donald Stanski<sup>1b</sup>

### **Affiliations:**

<sup>1</sup>Early Clinical Development, IMED Biotech Unit, AstraZeneca; <sup>1a</sup>Waltham, MA, USA;

<sup>1b</sup>Gaithersburg, MD, USA; <sup>1c</sup>Mölndal, Sweden; <sup>1d</sup>Cambridge, UK

<sup>2</sup>M&S Decisions, Moscow, Russia

<sup>3</sup>College of Public Health and College of Engineering, University of Georgia, Athens, GA, USA

\*To whom correspondence should be addressed: 35 Gatehouse Drive, Waltham MA, 02451, USA;  
Office: +1 617 306 9590, Email: gabriel.helmlinger@astrazeneca.com

Download English Version:

<https://daneshyari.com/en/article/8512103>

Download Persian Version:

<https://daneshyari.com/article/8512103>

[Daneshyari.com](https://daneshyari.com)